deferasirox has been researched along with amg531 in 5 studies
| Studies (deferasirox) | Trials (deferasirox) | Recent Studies (post-2010) (deferasirox) | Studies (amg531) | Trials (amg531) | Recent Studies (post-2010) (amg531) |
|---|---|---|---|---|---|
| 832 | 136 | 572 | 713 | 94 | 607 |
| Protein | Taxonomy | deferasirox (IC50) | amg531 (IC50) |
|---|---|---|---|
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 8.27 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.6605 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 3.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Argenziano, M; Casale, M; Perrotta, S; Punzo, F; Rossi, F; Tortora, C | 1 |
| Andreani, G; Cilloni, D; De Gobbi, M; Dragani, M; Saglio, G | 1 |
| Argenziano, M; Di Martino, M; Di Paola, A; Di Pinto, D; Perrotta, S; Pota, E; Punzo, F; Rossi, F; Tortora, C | 1 |
| Fu, R; Huang, L; Liu, C; Liu, Z; Tian, M | 1 |
1 review(s) available for deferasirox and amg531
| Article | Year |
|---|---|
Synergistic effect of eltrombopag and deferasirox in aplastic anemia: a clinical case and review of the literature.
Topics: Anemia, Aplastic; Benzoates; Deferasirox; Humans; Hydrazines; Pyrazoles | 2020 |
4 other study(ies) available for deferasirox and amg531
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis.
Topics: Adult; Benzoates; Blood Transfusion; Bone and Bones; Cell Differentiation; Deferasirox; Drug Evaluation; Female; Ferritins; Healthy Volunteers; Humans; Hydrazines; Iron; Iron Chelating Agents; Iron Overload; Leukocytes, Mononuclear; Osteoclasts; Osteoporosis; Primary Cell Culture; Pyrazoles; Receptors, Thrombopoietin; Thalassemia; Transfusion Reaction | 2018 |
Effects of Iron Chelation in Osteosarcoma.
Topics: Apoptosis; Benzoates; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deferasirox; Drug Therapy, Combination; Humans; Hydrazines; Iron Chelating Agents; Osteosarcoma; Pyrazoles; Treatment Outcome | 2021 |
Deferasirox combination with eltrombopag shows anti-myelodysplastic syndrome effects by enhancing iron deprivation-related apoptosis.
Topics: Apoptosis; Benzoates; Deferasirox; Humans; Hydrazines; Iron; Iron Chelating Agents; Myelodysplastic Syndromes; Pyrazoles; Thrombocytopenia | 2022 |